Digoxin use and heart failure outcomes: Results from the valsartan heart failure trial (Val-HeFT)

Congestive Heart Failure

Volumn 16, Issue 5, 2010, Pages 191-195

  Butler, Javed ^a   Anand, Inder S ^b,c   Kuskowski, Michael A ^b   Rector, Thomas ^b   Carson, Peter ^d   Cohn, Jay N ^c  

^a EMORY UNIVERSITY   (United States)

^b VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; VALSARTAN;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG USE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; DIGOXIN; DISEASE MANAGEMENT; FEMALE; HEART FAILURE; HEART RATE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MORTALITY; STROKE VOLUME; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 77957053929     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2010.00161.x     Document Type: Article

References (29)

1. Hunt SA, Abraham WT, Chin MH. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult - Summary Article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation- Endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
2. Swedberg K, Cleland J, Dargie H. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European society of cardiology. Eur Heart J 2005, 26:1115-1140.
3. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988, 259:539-544.
4. Dobbs RJ, Dobbs SM, Kenyon WI. Maintenance digoxin after an episode of heart failure. Br Med J 1977, 2:522-523.
5. Lee DC, Johnson RA, Bingham JB. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med 1982, 306:699-705.
6. Guyatt GH, Sullivan MJ, Fallen EL. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1988, 61:371-375.
7. DiBianco R, Shabetai R, Kostuk W. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989, 320:677-683.
8. Uretsky BF, Young JB, Shahidi FE. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993, 22:955-962.
9. Packer M, Gheorghiade M, Young JB. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993, 329:1-7.
10. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533.
11. Lader E, Egan D, Hunsberger S. The effect of digoxin on the quality of life in patients with heart failure. J Card Fail 2003, 9:4-12.
12. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002, 347:1403-1411.
13. Rathore SS, Curtis JP, Wang Y. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003, 289:871-878.
14. Domanski M, Fleg J, Bristow M, Knox S. The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail 2005, 11:83-86.
15. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
16. Levey AS, Bosch JP, Lewis JB. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
17. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17:2265-2281.
18. Poole-Wilson PA, Swedberg K, Cleland JG. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7-13.
19. Taylor AL, Ziesche S, Yancy C. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
20. Young JB, Dunlap ME, Pfeffer MA. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004, 110:2618-2626.
21. Bardy GH, Lee KL, Mark DB. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225-237.
22. Moss AJ, Zareba W, Hall WJ. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877-883.
23. Cleland JG, Daubert JC, Erdmann E. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352:1539-1549.
24. Adams KF, Gheorghiade M, Uretsky BF. Patients with mild heart failure worsen during withdrawal from digoxin therapy. J Am Coll Cardiol 1997, 30:42-48.
25. Anand IS, Chandrashekhar Y. Digitalis: The Curtain Comes Down. Heart Failure in Clinical Practice 2000, 225-244. McMurray JV, Cleland JG. eds, 2nd ed. Martin Dunitz Ltd, London, England
26. Pitt B, Remme W, Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
27. Packer M, Coats AJ, Fowler MB. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
28. Ruelaz RA, Rahimtoola SH. Was it digoxin toxicity?...very likely. J Card Fail 2005, 11:87-90.
29. Georgiopoulou V, Kalogeropoulos A, Giamouzis G. Utility of digoxin in patients with advanced heart failure on contemporary optimal medical therapy. Circ Heart Fail 2009, 2:90-97.